CIP
SUPN icon

Chartwell Investment Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Chartwell Investment Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-35,139
Closed -$969K – 442
2023
Q3 		$969K Hold
35,139
– – 0.04% 357
2023
Q2 		$1.06M Buy
+35,139
New +$1.23M 0.04% 349
2017
Q3 		– Sell
-49,280
Closed -$2.12M – 438
2017
Q2 		$2.12M Buy
+49,280
New +$1.75M 0.08% 286

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Chartwell Investment Partners's SUPN Position: Q4 2023 in Review

Chartwell Investment Partners sold out of Supernus Pharmaceuticals (SUPN) in Q4 2023, closing a stake of 35,139 shares — an estimated $969K sold.

Chartwell Investment Partners first reported a position in SUPN in Q2 2017 and held it in 3 quarters. The position peaked at $2.12M in Q2 2017. 246 funds tracked by Wall St. Rank hold SUPN as of Q4 2023.

  • Chartwell Investment Partners reported no remaining Supernus Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Chartwell Investment Partners sold 35,139 Supernus Pharmaceuticals shares in Q4 2023, an estimated $969K.
  • Chartwell Investment Partners first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 3 quarters.
  • Chartwell Investment Partners's Supernus Pharmaceuticals position peaked at $2.12M in Q2 2017.
  • 246 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2023.

Based on Chartwell Investment Partners's 13F filing for Q4 2023, filed 15 Feb 2024.